The Right Drug, Right Dose, Right Time: Using Genomic Data to Individualize Treatment (RIGHT)
RIGHT aimed to develop best practices for the implementation of genetic sequence data into clinical systems to improve patient outcomes. The researchers identified Mayo Clinic Biobank participants who were most likely to benefit from preemptive pharmacogenomics (PGx) testing among the Mayo Clinic Biobank participants, in the United States of America. Recruitment occurred between October 4, 2012 and March 20, 2013 and just over 1,000 participants consented and were enrolled. All participants provided a blood sample. Beginning in May 2016, the study began a targeted effort to further enroll an additional 10,000 participants, resulting in a total sample of just over 11,000 participants. The majority of the follow-up is conducted passively, via the patient’s electronic health record (EHR). Additionally, active follow-ups consisted of surveys in 2014, 2017, and 2020.
Study design
Cohort
Number of participants at first data collection
1,013 (participants)
Age at first data collection
≥ 18 years (participants)
Participant year of birth
Varied (participants)
Participant sex
All
Representative sample at baseline?
No
Sample features
Country
Year of first data collection
2012
Primary Institutions
Mayo Clinic
Profile paper DOI
Funders
Mayo Clinic
National Institutes of Health (NIH)
Ongoing?
Yes
Data types collected
- Physical or biological assessment (e.g. blood, saliva, gait, grip strength, anthropometry)
- Secondary data
- Self-report questionnaire – unspecified
- None
- None
- Healthcare data
Engagement
Keywords
